Shenyang Pharma Univ. ALK compound L6

Shenyang Pharma Univ. ALK compound L6: sourced facts only. name: "In addition, L6 was also capable of inhibiting ALK-resistant mutations, including ALKL1196M (3.9 nM) and ALKG1202R (5.2 nM)." [PMID:37737557]; target: "In addition, L6 was also capable of inhibiting ALK-resistant mutations, including ALKL1196M (3.9 nM) and ALKG1202R (5.2 nM)." [PMID:37737557]; developer: "Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, Shenyang, China." [PMID:37737557]; stage: "In particular, L6 bearing the 1-(6-methoxy-pyridin-2-yl)-4-(morpholinomethyl)piperidinyl-4-ol moiety was detected as the optimal compound against ALK-dependent cell lines of Karpas299 (0.017 μM) and H2228 cells (0.052 μM), in company with encouraging ALK enzyme inhibition (ALKWT , IC50 = 1.8 nM)." [PMID:37737557]